A PHASE I/II, MULTICENTER, OPEN-LABEL, NONCOMPARATIVE AIDS CLINCAL TRIALS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 在第一阶段，为了评估雷替格列韦的短期安全性和耐受性，在最初稳定的背景疗法的基础上，该疗法将在6个月至6个月的儿童和青少年年龄组中进行优化。月至2年，2年至12年，12年至19年。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In stage I, to evaluate the short term safety and tolerability of raltegravir added to an initial stable background therapy which will then be optimized in children and adolescents in the age groups of ???weeks to <6 months, ?? months to <2 years, ?2 to <12 years, and ?12 to <19 years.